Pathogens · 4 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes evidence linking the gut bacterial enzyme β-glucuronidase (GUS), part of the 'estrobolome', to estrogen metabolism and breast cancer risk and treatment. It proposes GUS as a potential molecular target for prevention and therapy, particularly for hormone receptor-positive breast cancer.
This narrative review discusses the role of the gut microbiome, specifically bacterial β-glucuronidase (GUS) enzymes, in estrogen metabolism and its potential link to hormone receptor-positive breast cancer. The review synthesizes preclinical and mechanistic evidence, including the concept of the 'estrobolome' and its interaction with diet and hormones. It highlights that bacterial GUS can reactivate estrogens and other compounds in the gut, potentially influencing cancer risk and drug metabolism, as seen with the chemotherapy drug irinotecan. The authors suggest that GUS enzymes represent a potential therapeutic target. The implications suggest future strategies involving microbiota modulators for prevention or as adjuvant therapies.
